Rh(D) immunoglobulin-VF (CSL Behring)

抗D免疫球蛋白（杰特贝林）

Report date: 2024/08/23 17:29:47

Base Information

Drug NameRh(D) immunoglobulin-VF (CSL Behring)
Drug Alias Name抗D免疫球蛋白（Seqirus）Human Anti-D Rho ImmunoglobulinRh factorRho(D) Immune GlobulinRhophylac
ClassificationBiologics > Protein drugs > ImmunoglobulinBiologics > Blood components
Mechanisms of ActionBlood group Rh(D) polypeptide modulatorsImmunoglobulin agonists
TargetsBlood group Rh(D) polypeptideImmunoglobulin
Therapy Area/IndicationsHematologic Diseases
Global Approved IndicationsHematologic Diseases
Approved Indications in ChinaN/A
Original Approved Country/TerritoryAustralia
Original Approved Date2010/10/01
Country/TerritoryAustralia
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaN/A
Originator CompaniesCsl Behring Llc
China Registration ClassN/A

Develop Information

Active CompaniesCsl Behring Llc
Inactive CompaniesN/A
Active IndicationsHematologic Diseases
Inactive IndicationsN/A

Other Information

ATC CodeJ06BB01
Related LinksN/A